- Home
- KOS vs SVRA Comparison
KOS vs SVRA Comparison
Compare KOS & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOS | SVRA |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2011 | 2009 |
Fundamental Metrics
Financial Performance| Metric | KOS | SVRA |
|---|---|---|
| Price | $2.96 | $5.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $1.91 | ★ $7.33 |
| AVG Volume (30 Days) | ★ 12.7M | 1.5M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,288,352,000.00 | N/A |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | N/A | $430.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.84 | $3.08 |
| 52 Week High | $3.34 | $7.01 |
Technical Indicators
Market Signals| Indicator | KOS | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 66.96 | 49.54 |
| Support Level | $2.68 | $5.26 |
| Resistance Level | $3.09 | $6.09 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 86.00 | 46.47 |
Price Performance
Historical ComparisonAbout KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).